OQS
GTBP icon

Occudo Quantitative Strategies’s GT Biopharma GTBP Stock Holding History

Occudo Quantitative Strategies’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-585
Closed -$31K – 1131
2022
Q3 		$31K Sell
585
-115
-16% -$8.8K ﹤0.01% 1119
2022
Q2 		$63K Buy
700
+31
+5% +$2.35K 0.01% 1050
2022
Q1 		$58K Sell
669
-101
-13% -$8.91K ﹤0.01% 1068
2021
Q4 		$70K Buy
+770
New +$115K 0.01% 992

Other funds holding GTBP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFS
Baskin Financial Services Toronto, Ontario, Canada $1.27B AUM 9.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Occudo Quantitative Strategies's GTBP Position: Q4 2022 in Review

Occudo Quantitative Strategies sold out of GT Biopharma (GTBP) in Q4 2022, closing a stake of 585 shares — an estimated $31K sold.

Occudo Quantitative Strategies first reported a position in GTBP in Q4 2021 and held it in 4 quarters. The position peaked at $70K in Q4 2021. 36 funds tracked by Wall St. Rank hold GTBP as of Q4 2022.

  • Occudo Quantitative Strategies reported no remaining GT Biopharma position as of Q4 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 585 GT Biopharma shares in Q4 2022, an estimated $31K.
  • Occudo Quantitative Strategies first reported a position in GT Biopharma in Q4 2021 and held it in 4 quarters.
  • Occudo Quantitative Strategies's GT Biopharma position peaked at $70K in Q4 2021.
  • 36 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.